LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Buy” by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $94.40.

A number of research analysts have recently commented on LMAT shares. Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Barrington Research reiterated an “outperform” rating and issued a $92.00 target price on shares of LeMaitre Vascular in a research report on Friday. Roth Mkm restated a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Finally, JMP Securities raised their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold 43,251 shares of company stock valued at $3,714,994 over the last ninety days. Corporate insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in LMAT. Truist Financial Corp increased its stake in shares of LeMaitre Vascular by 92.1% during the 2nd quarter. Truist Financial Corp now owns 7,054 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 3,381 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after purchasing an additional 90,573 shares during the period. The Manufacturers Life Insurance Company increased its position in LeMaitre Vascular by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 10,469 shares of the medical instruments supplier’s stock worth $861,000 after buying an additional 583 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of LeMaitre Vascular by 68.6% in the second quarter. AQR Capital Management LLC now owns 22,569 shares of the medical instruments supplier’s stock valued at $1,857,000 after buying an additional 9,183 shares during the period. Finally, Alpha DNA Investment Management LLC bought a new stake in shares of LeMaitre Vascular in the second quarter valued at $499,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 0.2 %

Shares of LMAT opened at $89.96 on Friday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $92.90. The stock has a market capitalization of $2.02 billion, a PE ratio of 59.58, a P/E/G ratio of 2.28 and a beta of 0.88. The firm’s 50 day moving average is $86.84 and its 200-day moving average is $77.99.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company posted $0.37 EPS. Equities research analysts predict that LeMaitre Vascular will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.71%. LeMaitre Vascular’s payout ratio is 42.38%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.